Cargando…

High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production

BACKGROUND: Limited data suggest that serious infections caused by Enterobacterales with a moderate to high risk of clinically significant AmpC production can be successfully treated with cefepime if the cefepime minimum inhibitory concentration (MIC) is ≤2 µg/mL. However, isolates with a cefepime-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunz Coyne, Ashlan J, El Ghali, Amer, Lucas, Kristen, Witucki, Paige, Rebold, Nicholas, Holger, Dana J, Veve, Michael P, Rybak, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034593/ https://www.ncbi.nlm.nih.gov/pubmed/36968970 http://dx.doi.org/10.1093/ofid/ofad034

Ejemplares similares

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
por: Rebold, Nicholas, et al.
Publicado: (2023)

Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023)

2775. Clinical Outcomes and Treatment-Emergent Resistance of Piperacillin-tazobactam, Cefepime, Carbapenems and Fluoroquinolones for the Treatment of Bloodstream Infections due to AmpC β-Lactamase-Producing Enterobacterales
por: Jawanda, Jasanjeet, et al.
Publicado: (2023)

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
por: Kunz Coyne, Ashlan J., et al.
Publicado: (2022)

2779. Early Administration of Ceftazidime-Avibactam for Carbapenem-Resistant Enterobacterales Is Associated with Improved Clinical Success
por: Coyne, Ashlan J Kunz, et al.
Publicado: (2023)

Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
por: Holger, Dana J., et al.
Publicado: (2022)

1033. Unexpected Allies: Vancomycin and Cefazolin Combination Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Caniff, Kaylee E, et al.
Publicado: (2023)

Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales
por: Ávila-Núñez, M., et al.
Publicado: (2023)

93. Leveraging Stewardship to Promote Narrower-spectrum Antibiotic Use for Low-risk AmpC Enterobacterales
por: Hardy, Megan E, et al.
Publicado: (2023)

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
por: Ghali, Amer El, et al.
Publicado: (2022)

The Frequency of Extended-Spectrum β-Lactamase Genes Harbored by Enterobacterales Isolates at High Risk for Clinically Significant Chromosomal ampC Expression
por: Hareza, Dariusz, et al.
Publicado: (2023)

The Novel CarbaLux Test for Carbapenemases and Carbapenem Deactivating AmpC Beta-Lactamases
por: Pfaendler, Hans Rudolf, et al.
Publicado: (2020)

High Prevalence of Plasmid-Mediated Quinolone Resistance among ESBL/AmpC-Producing Enterobacterales from Free-Living Birds in Poland
por: Furmanek-Blaszk, Beata, et al.
Publicado: (2023)

Characterization of Extended-Spectrum β-Lactamase-Producing and AmpC β-Lactamase-Producing Enterobacterales Isolated from Companion Animals in Korea
por: Shin, Se Ra, et al.
Publicado: (2021)

Risk Factors of Death in Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacterales in Patients with Neoplasia
por: da Cunha Ferreira, Tiago, et al.
Publicado: (2021)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

Detection of Extended-Spectrum β-Lactamases (ESBLs) and AmpC in Class A and Class B Carbapenemase-Producing Enterobacterales
por: Imkamp, Frank, et al.
Publicado: (2022)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial Pseudomonas aeruginosa
por: Muddassir, Maria, et al.
Publicado: (2021)

2066. Synergistic Bacteriophage-Antibiotic Combinations Against High Inoculum DNS MRSA
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023)

2431. Evaluation of Clinical Outcomes in Bacteremia Due to AmpC β-Lactamase Producing Organisms Stratified by Treatment
por: Carlson, Travis, et al.
Publicado: (2018)

160. Antimicrobial Prescribing Patterns in Bloodstream Infections Caused by Cefepime-Susceptible Extended Spectrum β-lactamase Enterobacterales
por: O’Rourke, Emerald, et al.
Publicado: (2022)

Efficacy and Safety of Cefmetazole for Bacteremia Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales vs Carbapenems: A Retrospective Study
por: Kashihara, Eriko, et al.
Publicado: (2023)

2118. Comparative Analysis of Cefiderocol Mono- and Combination Therapy for Multi-Drug Resistant Gram-negative Infections
por: Ghali, Amer El, et al.
Publicado: (2023)

Role of AmpR in the High Expression of the Plasmid-Encoded AmpC β-Lactamase CFE-1
por: Nakano, Ryuichi, et al.
Publicado: (2017)

Bloodstream Infections by AmpC-Producing Enterobacterales: Risk Factors and Therapeutic Outcome
por: Pospišil, Mladen, et al.
Publicado: (2023)

Extended-spectrum beta-lactamases screening agar with AmpC inhibition
por: Al Naiemi, N., et al.
Publicado: (2009)

2136. In Vitro Activity of Nacubactam (OP0595) Combined with Cefepime against Carbapenem-resistant Enterobacterales Isolated in Japan
por: Yanagihara, Katsunori, et al.
Publicado: (2023)

Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing Enterobacterales and Differentiation of Carbapenem-Resistant Enterobacterales
por: Takei, Kentarou, et al.
Publicado: (2023)

Controversies about extended-spectrum and AmpC beta-lactamases.
por: Thomson, K S
Publicado: (2001)

Detection of AmpC β Lactamases in Gram-negative Bacteria
por: Gupta, Gunjan, et al.
Publicado: (2014)

Challenges in detection of AmpC β-lactamases among Enterobacteriaceae
por: Joseph, Noyal Mariya, et al.
Publicado: (2013)

Detection of AmpC β-lactamases in gram-negative bacteria
por: Zhou, Qian, et al.
Publicado: (2022)

High Prevalence of AmpC β-Lactamases in Clinical Isolates of Escherichia coli in Ilam, Iran
por: Maleki, Abbas, et al.
Publicado: (2015)

2179. Clinical Characteristics And Outcomes of Peritoneal Dialysis-Related Peritonitis Infection by Ampc β-lactamase-producing Enterobacterales
por: Navarro, Alberto Ordinola, et al.
Publicado: (2023)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

Detection of AmpC-β-lactamases producing isolates among carbapenem resistant P. aeruginosa isolated from burn patient
por: Mirsalehian, Akbar, et al.
Publicado: (2014)

Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland
por: Kuch, Alicja, et al.
Publicado: (2020)

Whole Genome Sequencing of Extended-Spectrum- and AmpC- β-Lactamase-Positive Enterobacterales Isolated From Spinach Production in Gauteng Province, South Africa
por: Richter, Loandi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n2ie7aejg0s937nklpn1gmr60k